Rapamycin for treating MSA: A preclinical proof of concept study
Objective: To assess the effects of rapamycin on motor behavior, α-synuclein burden and surrogate markers of neurodegeneration in a transgenic mouse model of multiple system…Interaction of amyloidogenic proteins in pancreatic β cells from subjects with synuclenopathies
Objective: We have investigated whether deposits of phosphorylated α-synuclein might be present in pancreatic tissue of subjects with synucleinopathies. Background: Parkinson’s disease patients experience a…Effects of Glial Heme Oxygenase-1 on Neuronal Alpha-Synuclein in the GFAP.HMOX1 Mouse Model of Parkinson’s Disease
Objective: To determine whether astroglial HO-1 transduces environmental and endogenous stressors into patterns of neural damage which promote the toxicity of neuronal alpha-synuclein. Background: The…The Small Molecule Alpha-Synuclein Misfolding Inhibitor, NPT200-11, Produces Multiple Benefits in an Animal Model of Parkinson’s Disease
Objective: To evaluate effects of NPT200-11 on Parkinson’s disease (PD)-relevant outcomes including alpha-synuclein pathology, neurodegenerative markers and motor performance in transgenic mouse models of PD.…PBT434 prevents the accumulation of glial cell inclusions and insoluble alpha-synuclein in a mouse model of Multiple System Atrophy
Objective: To evaluate PBT434 in a transgenic mouse model of multiple system atrophy (MSA) Background: PBT434 is a novel quinazolinone inhibitor of iron-mediated protein accumulation…Salivary Alpha-Synuclein and tau in Parkinson’s Disease and Progressive Supranuclear Palsy
Objective: The aim of this study is to measure alpha-synuclein (a-syn) total, a-syn oligomers (a-syn olig) and total tau protein concentration in the saliva of…Enhancing protein palmitoylation is protective in alpha-synuclein dependent cytotoxicity
Objective: To determine if enhancement of protein palmitoylation benefits alpha-synuclein (aS) dependent vesicular trafficking defects and cytotoxicity. Background: Recent studies suggest that vesicular trafficking defects…A Phase 2A Study of Nilotinib in Patients with Advanced and Early Parkinson’s disease: Study Design
Objective: To assess the safety and tolerability of nilotinib (150-300 mg QD) in moderate/advanced and early/de novo Parkinson disease (PD) participants. Background: Studies in cell…Possible neurotoxic hazards of common adulterants in Tea among Drosophila; ascertainment of toxicity of Tea preparations from local shops of an Indian city
Objective: The present study assesses the neurotoxic implications of common adulterants of Tea in drosophila system in terms of tremor behaviour and neurochemical changes. Also…Bidirectional gut-to-brain and brain-to-gut propagation of α-synuclein pathology in non-human primates
Objective: The prototypic synucleinopathy Parkinson's disease (PD) is hypothesized to spread out from the enteric nervous system (i.e. the gut) via the vagal nerve up…
- « Previous Page
- 1
- …
- 35
- 36
- 37
- 38
- 39
- …
- 51
- Next Page »